financetom
Business
financetom
/
Business
/
What's Going On With Restaurant Chain Wingstop Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Restaurant Chain Wingstop Stock Today?
Feb 19, 2025 6:42 AM

Wingstop Inc ( WING ) shares are trading lower in premarket on Wednesday after the fourth-quarter FY24 earnings.

The company reported fourth-quarter sales growth of 27.4% year-on-year to $161.82 million, missing the analyst consensus estimate of $164.54 million.

System-wide sales increased 27.6% Y/Y to $1.2 billion, Domestic same-store sales increased 10.1% versus last year, and Digital sales jumped to 70.3% of system-wide sales. Domestic restaurant AUVs increased to $2.1 million.

Revenue from royalty, franchise fees, and others rose 31.2% Y/Y, Advertising fee revenue increased 30%, and company-owned restaurant sales grew 14.6%.

Total costs and expenses expanded 23.3% Y/Y to $119.98 million. The operating margin was 25.8%, and the operating income for the quarter gained 40.3% to $41.8 million.

Adjusted EBITDA of $56.3 million increased 44.2% Y/Y. EPS of $0.92 beat the consensus estimate of $0.87.

Also Read: Starbucks Plans To Open 500 New Stores In Middle East- Report

Wingstop ( WING ) held $336.8 million in cash and equivalents as of December 28. There were 2,563 Wingstop ( WING ) restaurants system-wide, including 2,204 restaurants in the U.S.

The company’s board of directors approved a quarterly dividend of $0.27 per share, which will be paid on March 28, 2025, to stockholders of record as of March 7, 2025.

As of December 28, 2024, $311.1 million remained available under the share repurchase program previously approved by the company's Board of Directors.

“We reached new highs with domestic AUVs of $2.1 million and opened 349 net new restaurants – a remarkable 15.8% growth rate, demonstrating the strength of our unit economics and confidence in our strategies by our Brand Partners,” said President and CEO Michael Skipworth.

FY25 Outlook: Wingstop ( WING ) sees low- to mid-single digit domestic same store sales growth. The company expects global unit growth rate of 14% to 15%. Wingstop ( WING ) sees depreciation and amortization of $29 million – $30 million.

Price Action: WING shares are trading lower by 10.5% at $274.00 in premarket at the last check Wednesday.

Read Next:

Tesla Files Fresh Lawsuit Against Matthews After Court Defeat

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CAMP4 Therapeutics Prices $75 Million IPO
CAMP4 Therapeutics Prices $75 Million IPO
Oct 11, 2024
07:33 AM EDT, 10/11/2024 (MT Newswires) -- CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million. Underwriters have been granted a 30-day option to buy up to about 1 million additional shares. Shares of the biotechnology company are expected to...
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
Oct 11, 2024
07:44 AM EDT, 10/11/2024 (MT Newswires) -- AGBA (AGBA) and Triller said Friday they have finalized all necessary steps for their upcoming merger, expected to be completed around Oct. 14, pending final Nasdaq approval. As part of the merger, AGBA will undergo a reverse stock split at a 4-to-1 ratio to comply with Nasdaq requirements. The reverse split will be...
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Oct 11, 2024
07:41 AM EDT, 10/11/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study. The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis...
BRIEF-Vecima Acquires Falcon V Systems
BRIEF-Vecima Acquires Falcon V Systems
Oct 11, 2024
Oct 11 (Reuters) - Vecima Networks Inc ( VNWTF ): * VECIMA ACQUIRES FALCON V SYSTEMS, PROVIDER OF INNOVATIVE SOFTWARE ORCHESTRATION PLATFORM FOR CABLE, FIBER, AND MOBILE ACCESS NETWORKS * VECIMA NETWORKS ( VNWTF ): CHARTER COMMUNICATIONS WILL BE INITIAL CUSTOMER, SIGNING MULTI-YEAR DEAL TO DEPLOY BOTH PRINCIPAL CORE & TEST SUITE Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved